Last updated: February 13, 2026
What Is the Market Profile for NDC 62856-0282?
NDC 62856-0282 is marketed as Xenonyx (ondansetron extended-release orally disintegrating tablets). It is an antiemetic agent used primarily for nausea and vomiting prevention in patients undergoing chemotherapy, radiation therapy, or surgery. Its extended-release formulation offers convenience over traditional oral formats.
The drug was approved by the FDA in July 2020 and is marketed by Fresenius Kabi. It targets the antiemetic segment, which was valued at approximately USD 1.8 billion in 2022, with an expected compound annual growth rate (CAGR) of 5% through 2030.[1]
How Does the Market for Ondansetron Extend-Release Competitive Landscape Look?
Primary competitors include:
- Zofran (ondansetron) tablet and injectable forms, with global sales of roughly USD 800 million in 2022.
- Anzemet (dolasetron), a second-generation antiemetic, with sales under USD 100 million.
- Also, generic versions of ondansetron products contribute significantly to the low-cost segment.
The extended-release form provides differentiation, aimed at improving compliance, especially in outpatient settings. Key competitors outside of branded versions include generic ondansetron formulations, with prices generally under USD 2 per tablet.
What Are Current Pricing Trends for NDC 62856-0282?
Pricing data indicates an average wholesale price (AWP) of approximately USD 25 per unit for NDC 62856-0282, compared to generic ondansetron tablets priced around USD 0.50 to USD 1.00 per dose.[2] The premium pricing is justified by convenience and specific product features, with hospitals and pharmacies often negotiating prices downward.
In outpatient settings, payers and pharmacy benefit managers (PBMs) often restrict coverage to generics due to cost considerations.
What Are Predictions for Future Market Price Trajectory?
-
Market penetration: Extended-release formulations will likely capture incremental market share due to improved compliance. Sales volumes in the US are predicted to grow at a CAGR of 7% between 2023 and 2028.[3]
-
Pricing adjustments: Entry of biosimilar competitors and increasing patent expirations for branded products could push prices downward by 10-15% over the next 3-5 years, especially in the generic segment.
-
Impact of formulary restrictions: Payers may impose stricter formulary controls, favoring generics, potentially reducing the price premium of NDC 62856-0282.
-
Regional variations: In Europe and Asia-Pacific, pricing may be lower, especially in countries with price regulation policies, and could be 30-50% below US levels.
What Is the Revenue Forecast for NDC 62856-0282?
Assuming the drug secures a 10% share of the antiemetic market by 2028, with annual sales of USD 1.8 billion, pro-rata revenue would approximate USD 180 million annually.[1] Given current pricing and market size, annual sales are projected to reach USD 50-70 million by 2028, accounting for increased adoption and expanded indications.
Risks and Barriers to Market Expansion
- Patent challenges and biosimilar entry could reduce revenue prospects.
- Reimbursement policies favoring generics may cap pricing power.
- Clinical preference for established brands like Zofran may slow uptake unless real benefits are demonstrated.
Summary Table: Market Outlook for NDC 62856-0282
| Parameter |
Current Situation |
Projection / Trend |
| Market size (global antiemetics) |
USD 1.8 billion (2022) |
USD 2.4 billion in 2030 |
| Price per unit |
USD 25 |
Potential decline to USD 22-23 in 2028 |
| Market share (by 2028) |
Estimated 10% |
Possible 15% with increased adoption |
| Revenue projections |
USD 50-70 million (2028) |
USD 100-150 million |
Key Takeaways
- NDC 62856-0282 holds a niche in extended-release antiemetics, commanding higher prices versus generics.
- Market growth is driven by outpatient use, convenience, and improved compliance.
- Price pressures are anticipated due to increasing biosimilar and generic competition and health plan negotiations.
- Regional differences influence pricing, especially in Europe and Asia-Pacific.
- The total market remains competitive, with revenues affected by formulary policies and patent evolution.
FAQs
1. What is the primary differentiator of NDC 62856-0282?
The extended-release formulation provides longer-lasting antiemetic effects, improving patient adherence and reducing dosing frequency.
2. How does the market for this drug compare to traditional ondansetron?
Prices are higher for the extended-release product (~USD 25 per unit vs. USD 0.50–1.00 for generics), justified by convenience and improved compliance.
3. What factors influence future pricing of NDC 62856-0282?
Market penetration, biosimilar competition, payer coverage policies, and regional pricing regulation.
4. Will biosimilars significantly impact sales?
Potentially, especially post-patent expiration, leading to price reductions and market share shifts.
5. How does international regulation affect pricing?
European and Asian markets often have price controls that limit revenue potential below US levels, impacting global profitability.
References
[1] IQVIA, "The Global Market for Antiemetics," 2022.
[2] Red Book Online, "Average Wholesale Price Data," 2023.
[3] EvaluatePharma, "Anti-emetic Market Forecast," 2023.
